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The authors regret that the description of the synthesis of bume-
pamine in the above-mentioned article lacked an important aspect and
is therefore incorrect.
The correct synthesis of bumepamine is given below.
The authors would like to apologise for any inconvenience caused.
2.2 Synthesis of bumepamine
Bumetanide (1) (500 mg, 1.37 mmol) was dissolved in 9 mL dry
N,N-dimethylformamide and N,N-diisopropylethylamine (765 μL, 4.39
mmol), followed by addition of aniline (250 μL, 2.74 mmol). The
mixture was cooled on an ice-bath. COMU (707 mg, 1.65 mmol) was
added in one portion and the mixture was gradually warmed to room
temperature and stirred for 16 h. The reaction was quenched with sa-
turated aqueous NaHCO3 solution and extracted twice with ethyl
acetate (EtOAc). The combined organic layers were washed with water,
brine and dried over Na2SO4. The crude product was purified by
column chromatography (toluene:EtOAc:Et3N, 3:2:0.01). The desired
product (2; the phenylamide of bumetanide) (540 mg, 1.22 mmol) was
obtained in 89% yield as a slightly yellow solid. 1H NMR (400 MHz, d4-
MeOH) δ 7.79 (d, J=2.1 Hz, 1H), 7.68–7.71 (m, 2H), 7.50 (d, J=2.1
Hz, 1H), 7.36–7.40 (m, 2H), 7.28–7.32 (m, 2H), 7.14–7.19 (m, 1H),
7.05–7.09 (m, 1H), 6.93–6.96 (m, 2H), 3.17 (t, J=6.7 Hz, 2H),
1.40–1.48 (m, 2H), 1.13–1.21 (m, 2H), 0.83 (t, J=7.3 Hz, 3H). 13C
NMR (100 MHz) d4-MeOH δ 167.83, 157.87, 144.02, 140.63, 139.74,
138.38, 133.97, 130.61, 129.82, 125.77, 124.01, 122.45, 116.66,
115.22, 114.88, 43.71, 32.03, 20.87, 14.03. HRMS (ESI) calculated for
C23H26N3O4S [M+H]+ 440.1644, found 440.1646.
Next, the phenylamide of bumetanide (2) (250 mg, 0.57 mmol) was
dissolved in 12 mL tetrahydrofuran and borane dimethylsulfide complex (90
μL, 0.95 mmol) was added at room temperature. The reaction mixture was
stirred for 16 h at 70 °C and cooled to room temperature. Since some starting
material was still present, an additional amount of the borane di-
methylsulfide complex (90 μL, 0.95 mmol) was added and the reaction was
stirred for 5 h at 70 °C. The reactionmixture was cooled to room temperature
and then quenched with half-saturated aqueous NaHCO3 solution. The
mixture was extracted three times with EtOAc and the combined organic
layers were dried over Na2SO4. The crude product was purified by column
chromatography (CH2Cl2:MeOH, 50:1). The obtained oily substance was
dried under vacuum for 4 hours and then dissolved in 10 mL dry diethyl
ether (Et2O). 2M HCl in Et2O (135 μL, 0.27 mmol) was added and the flask
left to stand for 10 minutes. The salt that was formed was filtered, washed
three times with Et2O and the desired product (3; bumepamine) (90 mg,
0.21 mmol) was obtained as a slightly beige solid in 37% yield. 1H NMR
(400 MHz, d4-MeOH) δ 7.52–7.60 (m, 3H), 7.44–7.46 (m, 2H), 7.33 (d,
J=2.0 Hz, 1H), 7.68–7.30 (m, 2H), 7.04–7.08 (m, 1H), 6.92 (d, J=2.0 Hz,
1H), 6.86–6.89 (m, 2H), 4.64 (s, 2H), 3.00 (t, J=6.8 Hz, 2H), 1.29–1.37 (m,
2H), 1.06–1.15 (m, 2H), 0.80 (t, J=7.4 Hz, 3H). 13C NMR (100 MHz) d4-
MeOH δ 157.9, 144.2, 139.1, 138.9, 136.1, 131.5, 131.1, 130.6, 129.8,
124.3, 124.0, 118.1, 116.8, 116.6, 56.5, 43.6, 31.8, 20.8, 14.0. HRMS (ESI)
calcd for C23H28N3O3S [M+H]+ 426.1851, found 426.1852.
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All reactions were carried out under positive pressure of argon, with
oven-dried glassware using standard Schlenk techniques. Dry solvents
were obtained from Acros Organics (Thermo Fisher, Karlsruhe,
Germany) in Acroseal bottles and used without further purification.
Aniline was distilled over CaH2 and used directly after distillation.
Bumetanide was purchased from Alfa Aesar (Thermo Fisher) and used
without further purification. Reactions were monitored by thin-layer
chromatography (0.2 mm, silica gel 60, F254, aluminium-backed,
Macherey-Nagel; Düren, Germany), with detection by UV light (254
nm). Flash chromatography was performed on Merck silica (60M).
NMR spectra were recorded on an AMX-400 instrument (Bruker) at 400
MHz or at 100 MHz for 1H and 13C, respectively. Deuterated methanol
was used as solvent and spectra were calibrated against the residual
solvent peak (3.31 ppm and 49.00 ppm for 1H and 13C, respectively).
Data are presented as follows: chemical shift (δ, ppm), multiplicity
(s= singlet, d= doublet, t= triplet, q= quadruplet, m=multiplet),
coupling constant (reported in Hertz (Hz)), integration. Electrospray
(ESI-HRMS) mass spectra were obtained using an Applied Biosystems
API 150EX LC/MS system.
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